Editorial| Volume 101, P64-66, July 2017

Implantable hormonal contraception for women aged over 45 years

      The progestogen-only implant is a long-acting reversible method of contraception (LARC). The primary mode of action is to prevent ovulation. The first contraceptive implant available in 1999 in the UK was Implanon which was a single, non-biodegradable, subdermal rod licensed for up to 3 years of use. In 2010 this was replaced by Nexplanon which has barium sulphate added to enable detection by X-ray. This implant contains 68 mg of the progestogen etonogestrel (ENG) and has a release rate of approximately 60–70 μg/day in weeks 5–6 decreasing to approximately 25–30 μg/day at the end of the third year [
      Faculty of Sexual & Reproductive Health Care Clinical Guidance.: Progestogen-only Implants.
      ]. It is registered in other countries worldwide including Australia and USA. In New Zealand Jadelle, a two-rod levonorgestrel (LNG) containing implant is available and is licensed to provide contraceptive protection for 5 years. Jadelle consists of two rods containing a total of 150 mg LNG which provides low progestogen doses; 40 μg/day/day at 1 year of use, decreasing to about 30 μg/day from 24 months till the fifth year [
      • FDA
      Jadelle (levonorgestrel Implants) for Subdermal Use.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Faculty of Sexual & Reproductive Health Care Clinical Guidance.: Progestogen-only Implants.
        2014 ( implants-feb-2014/ [Accessed 3 March, 2017])
        • FDA
        Jadelle (levonorgestrel Implants) for Subdermal Use.
        2017 ( (Accessed March 3, 2017))
        • National Institute for Health and Care Excellence (NICE)
        Long-acting Reversible Contraception: The Effective and Appropriate Use of Long-acting Reversible Contraception.
        2005 ( [Accessed 3 March, 2017)])
        • Trussell J.
        Contraceptive efficacy.
        in: Hatcher R. Trussell J. Nelson A.L. Cates W. Kowal D. Policar M. Contraceptive Technology. 20th Revised Edition). Ardent Media, New York, NY2011: 779-863
        • Glasier A.
        Implantable contraceptives for women:effectiveness, discontinuation rates, return of fertility and outcomes of pregnancies.
        Contraception. 2002; 65: 29-37
        • bpas Reproductive Review
        Issues in Abortion, Pregnancy and Birth. 29 May 2011.
        2011 ( (Accessed 3 March 2017))
      2. Faculty of Sexual & Reproductive Health Care Clinical Guidance: Contraception for Women over 40.
        2010 ( [Accessed 3 March, 2017])
        • Trussell J.
        • Guthrie K.A.
        Choosing a contraceptive: efficacy, safety, and personal considerations.
        in: Hatcher R.A. Trussell J. Nelson A.L. Cates W. Kowal D. Policar M. Contraceptive Technology. Twentieth Revised edition. Ardent media, New York NY2011: 45-74
        • Faculty of Sexual & Reproductive Health Care
        UK Medical Eligibility Criteria for Contraceptive Use (UKMEC 2016).
        2016 ( (Accessed 3 March 2017))
        • Lopez L.M.
        • Bernholc A.
        • Chen M.
        • Grey T.W.
        • Otterness C.
        • Westhoff C.
        • Edelman A.
        • Helmerhorst F.M.
        Hormonal contraceptives for contraception in overweight or obese women.
        Cochrane Database Syst. Rev. 2016; 8 (Art. No.: CD008452)
        • Roberts H.
        • Hickey M.
        • Lethaby A.
        Hormone therapy in postmenopausal women and risk of endometrial hyperplasia: a cochrane review summary.
        Maturitas. 2014; 77: 4-6
        • Trimmer C.J.
        • Srivastava N.
        • Dieben Th.O.M
        • Cohen A.F.
        Boiavailability and bioequivalence from two oral formulations of desogestrel: Cerazette and Liseta.
        Eur. J. Drug Metab. Pharmacokinet. 1999; 24: 335-343
        • Ali M.
        • Akin A.
        • Bahamondes L.
        • Brache V.
        • Habib N.
        • Landoulsi S.
        • Hubacher D.
        for the WHO study group on subdermal contraceptive implants for women. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.
        Hum. Reprod. 2016; 31: 2491-2498
        • Turok D.K.
        • Gawron L.M.
        • Lawson S.
        New developments in long-acting reversible contraception: the promise of intrauterine devices and implants to improve family planning services.
        Fertil. Steril. 2016; 106: 1273-1281